Belotecan

DRUG4 trials

Sponsors

Chonnam National University Hospital, Chong Kun Dang Pharmaceutical

Conditions

Carcinoma, Non-Small-Cell LungCarcinoma, Small CellEpithelial Ovarian CancerSmall Cell Lung Cancer

Phase 2

Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy

CompletedNCT01022671

Chong Kun Dang PharmaceuticalCarcinoma, Non-Small-Cell Lung

Start: 2009-09-30End: 2010-03-31Updated: 2016-01-28

A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer

CompletedNCT01497873

Chong Kun Dang PharmaceuticalSmall Cell Lung Cancer

Start: 2010-09-30End: 2018-03-31Updated: 2018-12-27

Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial

CompletedNCT01630018

Chong Kun Dang PharmaceuticalEpithelial Ovarian Cancer

Start: 2011-01-31End: 2014-06-30Updated: 2016-09-22

Phase 3

Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient

CompletedNCT00826644

Chonnam National University HospitalCarcinoma, Small Cell

Start: 2009-01-31End: 2013-02-28Updated: 2021-08-09

Related Papers

A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer.

2020-09-307 citations

Safety of belotecan as second-line treatment for recurrent small cell lung cancer: A phase IIb randomized multicenter study

Annals of Oncology2018-10-01

Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial

BMC Cancer2016-08-2619 citations

Efficacy and safety comparison between belotecan and topotecan in patients with recurrent or refractory ovarian cancer: A multi-center, randomized, open-labelled, parallel-group phase IIb trial.

Journal of Clinical Oncology2015-05-20